Aim: To investigate the safety and efficacy of BioChaperone Lispo (BCLIS), an ultra-rapid formulation of insulin lispro (LIS) in people with type 1 diabetes.
Company]; 2.68-fold higher area under the curve [AUC] Insulin 0-30 minutes ), with similar total exposure at a dose of 0.2 U/kg and a reduction of 61% in incremental area under the blood glucose concentration-time curve from 0 to 2 hours after a meal (ΔAUC BG 0-2 hour ) vs LIS after a liquid meal test. 2 In addition, a proportional doseexposure relationship was shown in the range of 0.1 to 0.4 U/kg. 3 In the present study, we investigated the pharmacodynamic (PD) and pharmacokinetic (PK) characteristics, safety and tolerability of BCLIS by comparing the postprandial BG response to individualized solid mixed meal tests (MMTs) with BCLIS or LIS injected before, at, or after a meal in people with T1DM.
| MATERIALS AND METHODS

| Study design
This was a randomized, single-centre, double-blind, active comparator-controlled, multiple-daily-dose, two-period 14-day crossover phase I trial in 36 people with T1DM. The design of each 14-day treatment period is shown in Figure 1 .
The trial was approved by the local ethics committee and health authorities in accordance with Good Clinical Practice Guidelines (International Conference on Harmonization) and the Declaration of Helsinki. All participants gave written informed consent prior to initiation of any study-related activity. This study was registered at clinicaltrials.gov (NCT02528396).
| Participants
Men and women aged 18-64 years (both inclusive) with T1DM for ≥12 months, glycated haemoglobin (HbA1c) concentration ≤75 mmol/ mol, fasting C-peptide level ≤0.30 nmol/L, body mass index (BMI) between 18.5 and 28.0 kg/m 2 (both inclusive), and on stable insulin regimens with multiple daily insulin injections for at least 12 months prior to inclusion, with a total insulin dose <1.2 (I)U/kg/d, were enrolled at Profil, Neuss, Germany. People with clinically relevant diseases, a history of ketoacidosis, recurrent severe hypoglycaemia and hypoglycaemia unawareness were excluded.
| Treatments
Participants self-administered individualized bolus doses of BCLIS or LIS for 14 days, followed by a washout period lasting 1-14 days to mitigate any carryover effects from the previous period, and then crossed over to the other treatment with random allocation to treatment sequences. Participants were instructed not to change their basal insulin regimen unless medically required.
| Assessments
Participants arrived at the clinic in the evening of days −1 and 13, and received a standardized dinner. In the morning of days 1, 2, 3 and 14, after BG had been adjusted to 7.0 mmol/L AE 10% prior to the meal with intravenous glucose or insulin, a solid mixed meal with a size individualized for BMI and gender, identical on all study days, was served. The meal content consisted of 21% protein, 29% fat and 50%
carbohydrates. An individualized dose of BCLIS or LIS, based on the participant's usual insulin-to-carbohydrate ratio and the carbohydrate content of the meal, was administered. For each participant, the individualized dose of insulin was the same for BCLIS and LIS and for all
MMTs. Randomization also determined the sequence of time of insulin administration on days 1, 2 and 3 at −15, 0 or +15 minutes relative to the meal start at t0. Insulin on day 14 was administered at t0. Blood was sampled before the meal, which was ingested within 15 minutes, and frequently thereafter up to 360 minutes. The MMT glucose endpoints were measured using the Super GL glucose analyser (Dr Müller Gerätebau GmbH, Freital, Germany). Hypoglycaemia was defined as a BG value <3.5 mmol/L (plasma equivalent 3.9 mmol/L).
The PK measurements of insulin lispro concentrations were carried out on the 2 days with insulin administration at t0. Insulin lispro concentrations in serum were measured using a validated enzymelinked immunosorbent assay specific for insulin lispro, by Charles River Laboratories, Senneville, Canada. The lower limit of quantification of the method was 50 pg/mL for insulin lispro.
During the outpatient period from day 3 to day 13, participants injected themselves with their individualized dose of BCLIS or LIS and their regimen of basal insulin. The participants recorded each injected dose of bolus or basal insulin, their meals, and any adverse event, including hypoglycaemic episodes, in a diary. In addition, the participants had to perform and document at least 4 self-monitored BG measurements per day (before breakfast, before lunch, before dinner and at bedtime). During dosing visits, injection sites were marked and assessed for spontaneous pain, pain on palpation, itching, redness, oedema and induration/infiltration.
Each was scored 0 (none), 1 (mild), 2 (moderate) or 3 (severe). This assessment was also done after 1 week of treatment and at the final follow-up.
| Statistical methods
The sample size calculation was based on the primary endpoint In case of negative values, endpoints were analysed on the linear scale. For these endpoints, treatment ratios and 90% or 95% CIs were calculated using Fieller's method. Variables that were neither normally nor log-normally distributed were analysed using the Wilcoxon signed-rank test based on a 2-sided α level of 5%. Hodges-Lehmann estimates and 95% CIs were calculated for these variables.
A post hoc analysis was carried out to compare LS means between BCLIS and LIS on day 14, using a similar mixed-effect linear model without dose-meal interval effect.
3 | RESULTS
| Participant disposition and characteristics
Of 40 participants screened, 36 were randomized and exposed to a trial insulin. Twenty-five of the participants were men (69.4%). The
mean HbA1c was 55 AE 5 mmol/mol and C-peptide level was below the limit of quantification (interquartile range below limit of quantification −0.14 nmol/L). A total of 15 participants were on glargine U-100 (4 of these injecting twice daily), 14 were on insulin detemir (10 injecting twice daily), 1 was on insulin degludec once daily and 6 were on NPH twice daily.
A total of 35 participants completed the trial; 1 participant dropped out because of an adverse event deemed unlikely to be related to treatment before completion of the first treatment period (BCLIS).
| BG profiles
With administration immediately before meal start on days 1 to 3, glycaemic excursions were significantly lower (31%; P = 0.0237) in the first 2 hours after dosing with BCLIS compared with LIS ( Figure 2A and Table 1 ), whereas there was no difference over the full 6-hour postprandial period ( Figure 2B and Table 1 ). Postprandial BG excursions improved over the 14 days of treatment with both BCLIS and LIS, but the difference in the first 2 hours in favour of BCLIS was maintained ( Figure 3A and B and Table 1 
| Pharmacokinetics
BCLIS was absorbed faster than LIS on days 1 to 3 ( Figure 2C and D and Table 1 ) and this difference was maintained until day 14 ( Figure 3C and D and Table 1 ). The primary PK endpoint AUC lis 0-30 minutes was 74% higher with BCLIS than with LIS on days 1 to 3 (P < 0.0001; Table 1 ). In addition, both early and late time to reach half maximal serum insulin lispro concentration T 0.5 max were reached earlier with BCLIS, indicating a "faster in and out" PK profile (Table 1) . Finally, exposure to insulin lispro was similar for BCLIS and LIS.
There was no difference in any PK endpoints between days 1, 2 or 3 and day 14 within treatment with BCLIS.
| Insulin use during the trial
The mean total basal insulin doses per day were similar for BCLIS and a Indicates a significant difference within treatment between days 1 and 2 and day 14 (P < 0.1).
| DISCUSSION
The present study demonstrated a 31% improvement in early postprandial BG excursions after a mixed meal, the primary endpoint, with BCLIS compared with LIS at t0. This is explained by the faster absorption of insulin lispro with the BCLIS formulation than with LIS. This difference was maintained over a 14-day period. The improved early postprandial BG excursion was also seen with administration after the meal, but not with administration 15 minutes before the meal. No safety concerns were raised for BCLIS.
In general, dosing at the start of the meal seems preferred from the patient perspective. The ultra-rapid profile of BCLIS allows for such timing of administration, without compromising efficacy, even as compared with the administration of LIS 15 minutes before the meal.
Dosing of insulin before the meal could be an alternative for some patients, but is associated with an initial decline in BG levels which may result in premeal hypoglycaemia. 4 Dosing after the meal always seems to result in larger postprandial BG excursions; however, when this is unavoidable, such as when the amount of food taken is unpredictable, postmeal dosing of an ultra-rapid insulin analogue formulation seems to limit postprandial BG excursions compared with a conventional rapid-acting analogue. BCLIS may, therefore, offer flexibility of the timing of injection with limited impact on the postprandial BG control vs LIS.
Limitations of this research include the need for standardized identical meals taken with each insulin formulation in order to limit 
